Breaking Finance News

A report released today by Vetr Inc. about Juno Therapeutics Inc (NASDAQ:JUNO) bumps the target price to $27.60

Vetr Inc. increased the stock price target of Juno Therapeutics Inc (NASDAQ:JUNO) to $27.60 reporting a potential upside of 0.12%.

Just yesterday Juno Therapeutics Inc (NASDAQ:JUNO) traded -0.69% lower at $24.66. Juno Therapeutics Inc’s 50-day moving average is $34.04 and its 200-day moving average is $27.13. The last stock price is down 63.31% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 3,335,682 shares of JUNO traded hands, up from an average trading volume of 2,640,580

Recent Performance Chart

Juno Therapeutics Inc (NASDAQ:JUNO)

Juno Therapeutics Inc has 52 week low of $17.52 and a 52 week high of $47.00 and has a market capitalization of $0.

In addition to Vetr Inc. reporting its stock price target, a total of 11 brokerages have issued a ratings update on the company. The average stock price target is $55.73 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Juno Therapeutics Inc (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.